In this study, we aimed to evaluate the efficacy of Osimertinib in patients with EGFR mutant NSCLC who have developed EGFR T790M acquired resistance to first- and second-generation EGFR TKIs, detected in plasma using ddPCR. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.